Press "Enter" to skip to content

Switzerland's Novartis sees 2019 drug unit growth as it narrows focus

BASEL, Switzerland (Reuters) – Swiss drugmaker Novartis sees sales and profit growth from its core businesses in 2019 as it sheds its Alcon eyecare unit and a U.S.

Please follow and like us:

Comments are closed.